Pharmacokinetic/pharmacodynamic insulin-glucose analysis for differentiation of beta-cell function: an 18 month follow-up study in pre-pubertal lean and obese children

2006 ◽  
Vol 27 (6) ◽  
pp. 257-265
Author(s):  
N. Gupta ◽  
R.P. Hoffman ◽  
P. Veng-Pedersen
Keyword(s):  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Obese Children ◽  
Follow Up Study ◽  
Glucose Analysis

A Follow-up Study of Cell-Mediated Cytotoxicity and Beta Cell Function in Type I Diabetes1)

2009 ◽  
Vol 89 (03) ◽  
pp. 363-367 ◽  
Author(s):  
B. Bierwolf ◽  
H.-J. Verlohren ◽  
D. Lohmann ◽  
E. F. Lampeter ◽  
J. Krug
Keyword(s):  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Type I ◽  
Follow Up Study

Correlation between residual beta-cell function and islet cell antibodies in newly diagnosed type I diabetes. Follow-up study

Diabetes ◽  
1989 ◽  
Vol 38 (11) ◽  
pp. 1396-1401 ◽  
Author(s):  
M. Peig ◽  
R. Gomis ◽  
G. Ercilla ◽  
R. Casamitjana ◽  
G. F. Bottazzo ◽  
...  
Keyword(s):  
Beta Cell ◽  
Beta Cell Function ◽  
Islet Cell ◽  
Cell Function ◽  
Type I Diabetes ◽  
Islet Cell Antibodies ◽  
Type I ◽  
Newly Diagnosed ◽  
Follow Up Study

Four-Year Follow-Up of Glucose Tolerance and Beta-Cell Function in Nondiabetic Cystic Fibrosis Patients

1995 ◽  
Vol 44 (2) ◽  
pp. 45-50 ◽  
Author(s):  
F. De Luca ◽  
T. Arrigo ◽  
A. Di Benedetto ◽  
A. Tedeschi ◽  
C. Sferlazzas ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Glucose Tolerance ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function

scholarly journals Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Nils B. Jørgensen ◽  
Kirstine N. Bojsen-Møller ◽  
Carsten Dirksen ◽  
Christoffer Martinussen ◽  
Maria S. Svane ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Gastric Bypass ◽  
Glucose Metabolism ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Relative Change

Abstract To describe glucose metabolism in the late, weight stable phase after Roux-en-Y Gastric Bypass (RYGB) in patients with and without preoperative type 2 diabetes we invited 55 RYGB-operated persons from two existing cohorts to participate in a late follow-up study. 44 (24 with normal glucose tolerance (NGT)/20 with type 2 diabetes (T2D) before surgery) accepted the invitation (median follow-up 2.7 [Range 2.2–5.0 years]). Subjects were examined during an oral glucose stimulus and results compared to preoperative and 1-year (1 y) post RYGB results. Glucose tolerance, insulin resistance, beta-cell function and incretin hormone secretion were evaluated. 1 y weight loss was maintained late after surgery. Glycemic control, insulin resistance, beta-cell function and GLP-1 remained improved late after surgery in both groups. In NGT subjects, nadir glucose decreased 1 y after RYGB, but did not change further. In T2D patients, relative change in weight from 1 y to late after RYGB correlated with relative change in fasting glucose and HbA1c, whereas relative changes in glucose-stimulated insulin release correlated inversely with relative changes in postprandial glucose excursions. In NGT subjects, relative changes in postprandial nadir glucose correlated with changes in beta-cell glucose sensitivity. Thus, effects of RYGB on weight and glucose metabolism are maintained late after surgery in patients with and without preoperative T2D. Weight loss and improved beta-cell function both contribute to maintenance of long-term glycemic control in patients with type 2 diabetes, and increased glucose stimulated insulin secretion may contribute to postprandial hypoglycemia in NGT subjects.

Beta Cell Function, Incretin Hormones and Incretin Effect in Obese Children and Adolescents with Prediabetes

2021 ◽  
Author(s):  
Natee Sakornyutthadej ◽  
Pat Mahachoklertwattana ◽  
Suwannee Chanprasertyothin ◽  
Sarunyu Pongratanakul ◽  
Patcharin Khlairit ◽  
...  
Keyword(s):  
Beta Cell ◽  
Children And Adolescents ◽  
Beta Cell Function ◽  
Cell Function ◽  
Incretin Hormones ◽  
Incretin Effect ◽  
Obese Children

scholarly journals Post-intervention Effects of Varying Treatment Arms on Glycemic Failure and Beta-Cell Function in the TODAY Study

2020 ◽  
Author(s):  
Rachelle Gandica ◽  
Barbara H. Braffett ◽  
Lorraine E. Levitt Katz ◽  
Neil H. White ◽  
Jeanie B. Tryggestad ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Failure Rates ◽  
Post Intervention ◽  
Group Assignment ◽  
Original Treatment

<b>Objective</b>: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that glycemic failure rates were significantly lower in youth randomized to metformin plus rosiglitazone treatment compared to metformin alone or metformin plus intensive lifestyle intervention. At end of study, rosiglitazone was permanently discontinued, and routine diabetes care resumed. Herein, we report post-intervention glycemic failure rates in TODAY participants over an additional 36 months of follow-up for the three original treatment arms and describe insulin sensitivity and beta-cell function outcomes. <p><b>Research Design and Methods</b>: A total of 699 participants were randomized during TODAY, of whom 572 enrolled in the TODAY2 observational follow-up. Glycemic failure was defined as HbA1c ≥8% over a 6-month period or inability to wean from temporary insulin therapy within 3 months after acute metabolic decompensation during TODAY or a sustained HbA1c ≥8% over two consecutive visits during TODAY2. Oral glucose tolerance tests were conducted and insulin sensitivity, insulinogenic index, and oral disposition index (oDI) were calculated.</p> <p><b>Results</b>: During the 36 months of TODAY2, glycemic failure rates did not differ among participants by original treatment group assignment. Insulin sensitivity and beta-cell function deteriorated rapidly during the 36 months of TODAY2 routine diabetes care, but did not differ by treatment group assignment.</p> <p><b>Conclusions</b>: The added benefit of preventing glycemic failure by using rosiglitazone as a second agent in youth-onset type 2 diabetes did not persist after its discontinuation. More work is needed to address this rapid progression to avoid long-term diabetes complications.</p>

scholarly journals Post-intervention Effects of Varying Treatment Arms on Glycemic Failure and Beta-Cell Function in the TODAY Study

2020 ◽  
Author(s):  
Rachelle Gandica ◽  
Barbara H. Braffett ◽  
Lorraine E. Levitt Katz ◽  
Neil H. White ◽  
Jeanie B. Tryggestad ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Failure Rates ◽  
Post Intervention ◽  
Group Assignment ◽  
Original Treatment

<b>Objective</b>: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that glycemic failure rates were significantly lower in youth randomized to metformin plus rosiglitazone treatment compared to metformin alone or metformin plus intensive lifestyle intervention. At end of study, rosiglitazone was permanently discontinued, and routine diabetes care resumed. Herein, we report post-intervention glycemic failure rates in TODAY participants over an additional 36 months of follow-up for the three original treatment arms and describe insulin sensitivity and beta-cell function outcomes. <p><b>Research Design and Methods</b>: A total of 699 participants were randomized during TODAY, of whom 572 enrolled in the TODAY2 observational follow-up. Glycemic failure was defined as HbA1c ≥8% over a 6-month period or inability to wean from temporary insulin therapy within 3 months after acute metabolic decompensation during TODAY or a sustained HbA1c ≥8% over two consecutive visits during TODAY2. Oral glucose tolerance tests were conducted and insulin sensitivity, insulinogenic index, and oral disposition index (oDI) were calculated.</p> <p><b>Results</b>: During the 36 months of TODAY2, glycemic failure rates did not differ among participants by original treatment group assignment. Insulin sensitivity and beta-cell function deteriorated rapidly during the 36 months of TODAY2 routine diabetes care, but did not differ by treatment group assignment.</p> <p><b>Conclusions</b>: The added benefit of preventing glycemic failure by using rosiglitazone as a second agent in youth-onset type 2 diabetes did not persist after its discontinuation. More work is needed to address this rapid progression to avoid long-term diabetes complications.</p>

Sign in / Sign up

Export Citation Format

Share Document